Program for all days

• REMODEL Trial Overview: Framework and Key Outcomes
  PetterBjornstad Speaker United States
• Semaglutide Improves Kidney Outcomes Regardless Of SGLT2i Use In People With Chronic Kidney Disease And Type 2 Diabetes: Post-hoc Analysis The Remodel Trial
  DavidCherney Speaker Canada
• Aldosterone Blockade for Health Improvement Evaluation in End-stage Renal Disease Trial
  (ACHIEVE)
  MichaelWalsh Speaker lastwalsh1975@gmail.comCanada
• B-cell Targeted Therapy for Idiopathic Nephrotic Syndrome: Results of the Phase III Global Multicenter Inshore Trial Evaluating Efficacy and Safety of Obinutuzumab vs Mycophenolate Mofetil
  JulienHogan Speaker France
• Q&A Session

• RESOLVE Trial: Sodium Concentration in Dialysis Populations — a Global Cluster Randomized Study
  MegJardine Speaker meg.jardine@sydney.edu.auAustralia
• Q&A
• Key Aspects of the VOICE Clinical Trial on Anemia in Dialysis Patients
  ShuchiAnand Speaker sanand3@health.ucdavis.eduUnited States
• Q&A
• The Renal Life Cycle: Development, Maturity, and Decline
  HiddoLambers Heerspink Speaker h.j.lambers.heerspink@umcg.nlNetherlands
• Q&A
• Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-proven Primary Glomerular Diseases: Multi-center, Multi-arm and Multi-stage- the Story So Far
  Joint Presentation
  Selvin Sundar RajMani Speaker India

  SuceenaAlexander Speaker suceena@gmail.comIndia
• Q&A
• ASPIRE Trial: Aspirin Use in Dialysis Patients in China
  XueqingYU Speaker China
• Q&A

• Opening & Introduction
  Sydney Tang Speaker Hong Kong, China
• Efficacy and Safety Results of Atrasentan in Patients With IgA Nephropathy on Sodium‚ äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (Assist)
  HiddoLambers Heerspink Speaker h.j.lambers.heerspink@umcg.nlNetherlands
• Q&A
• Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial
  XiaobingYang Speaker China
• Q&A
• Efficacy and Safety of Iptacopan in Patients With IgA Nephropathy (IgAN): Final 24-month Results From the Phase III APPLAUSE-IgAN Study
  VladoPerkovic Speaker Australia
• Q&A
• Closing Remarks

• Effect of a 12-week Intradialytic Cycling Intervention on Hemodialysis-induced Myocardial Stunning: A Multi-centre Randomized Controlled Trial
  ClaraBohm Speaker Canada
• TEACH-PD Cluster Randomized Controlled Trial: Targeted Education ApproaCH to improve Peritoneal Dialysis Outcomes
  JosephineChow Speaker Australia
• Effect of Finerenone on Circulating Biomarkers: A CONFIDENCE Analysis
  MarioBerger Speaker mario.berger@bayer.comGermany
• Effect of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-creatinine Ratio by Age and Sex in the CONFIDENCE Trial
  RajivAgarwal Speaker United States
• Estimated Glomerular Filtration Rate, Systolic Blood Pressure, and Urinary Albumin-to-creatinine Ratio — Unravelling the Interplay in Combination: Findings From the CONFIDENCE Trial
  RajivAgarwal Speaker United States
• Lowering-Hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Prospective, Multicenter, Double Blind Randomized Controlled Trial
  Naya Huang Speaker huangnaya@163.comChina